Article info
Law, ethics and medicine
Paper
A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- Correspondence to Professor Yvonne Denier, Centre for Biomedical Ethics and Law, Faculty of Medicine, KU Leuven, Kapucijnenvoer 35 box 7001, Leuven 3000, Belgium; yvonne.denier{at}med.kuleuven.be
Citation
A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
Publication history
- Received July 8, 2011
- Revised July 29, 2011
- Accepted August 16, 2011
- First published September 24, 2011.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Should rare diseases get special treatment?
- Rare neurological diseases: a practical approach to management
- Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
- Ethical issues in funding orphan drug research and development
- Orphan drugs and the NHS: should we value rarity?
- Criteria to define rare diseases and orphan drugs: a systematic review protocol
- Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU
- Commissioning for rare diseases: view from the frontline